Can delayed intestinal transit prolong ochratoxin A re-exposure and persistence?

Ochratoxin A (OTA) is a slowly eliminated foodborne mycotoxin with potential kidney toxicity. The central premise is biologically credible, but the transit-specific implication remains mechanistic rather than clinically demonstrated in people.

Enterohepatic cycling and persistence

• Animal toxicokinetic studies support OTA enterohepatic recirculation: OTA is detectable in rat bile for up to 6 hours after dosing, and secondary peaks in serum and intestinal contents are consistent with biliary secretion followed by intestinal reabsorption.
• Functional intervention evidence is concordant. Interrupting bile-salt circulation lowers rat plasma OTA. Cholestyramine reduced plasma OTA, increased fecal toxin excretion, and reduced nephrotoxicity in OTA-fed rats; activated charcoal reduced blood and tissue OTA concentrations dose-dependently in pigs.
• These findings establish that biliary delivery can re-expose the intestine to OTA and that reabsorption can contribute to systemic persistence in experimental animals.

Delayed transit: mechanistic implications

• If OTA-containing bile remains in the intestinal lumen longer during delayed transit, there is plausibly more time for absorptive contact and reuptake. This could extend both intestinal re-exposure and circulating OTA persistence.
• Potential contributors include biliary handling, intestinal absorption, microbiome-mediated hydrolysis of conjugated OTA, and strong serum-protein binding. The latter is likely important independently of transit.

Human relevance

• Direct human evidence is lacking: no studies compare OTA blood levels, clearance, or half-life in constipation or objectively measured slow transit versus normal transit.
• In one radiolabeled human study, terminal plasma half-life was estimated at approximately 35 days with very low renal clearance. This confirms slow elimination but does not identify enterohepatic recirculation—or constipation—as its cause.

Bottom line

• OTA enterohepatic recirculation is well supported in animals; delayed intestinal transit is a plausible modifier of intestinal and systemic OTA exposure, but it is not an established constipation-specific effect in humans.